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Background: Studies evaluating the presence of viral sequences in breast cancer (BC), including various strains of
human papillomavirus and human herpes virus, have yielded conflicting results. Most were based on RT-PCR and
in situ hybridization.
Methods: In this report we searched for expressed viral sequences in 58 BC transcriptomes using five distinct
in silico methods. In addition, we complemented our RNA sequencing results with exome sequencing, PCR and
immunohistochemistry (IHC) analyses. A control sample was used to test our in silico methods.
Results: All of the computational methods correctly detected viral sequences in the control sample. We identified a
small number of viral sequences belonging to human herpesvirus 4 and 6 and Merkel cell polyomavirus. The extremely
low expression levels—two orders of magnitude lower than in a typical hepatitis B virus infection in hepatocellular
carcinoma—did not suggest active infections. The presence of viral elements was confirmed in sample-matched exome
sequences, but could not be confirmed by PCR or IHC.
Conclusions: Our results show that no viral sequences are expressed in significant amounts in the BC investigated. The
presence of non-transcribed viral DNA cannot be excluded.
Keywords: Breast cancer, Virus discovery, Next-generation sequencing, RNA-seq, ExomeBackground
Various risk factors have been linked with breast cancer,
including sex, age, family history of cancer, radiation and
others [1]. However, the underlying mechanisms in
breast carcinogenesis are not fully understood. Viral
infections have long been considered a risk factor in
several types of cancer. For example, the human papil-
lomavirus (HPV) contributes to cervical and head and
neck cancer, while the human herpesvirus 4 (EBV) con-
tributes to Burkitt’s lymphoma. Potential carcinogenetic
mechanisms include expression of viral oncogenes or in-
activation of tumor suppressors. For example, in cervical
cancer the expression of HPV viral oncoproteins E6 induces
the degradation of the tumor suppressor gene p53 [2].
Numerous investigators have tried to establish a link
between breast cancer and viral infections. The results,* Correspondence: vdetours@ulb.ac.be
1IRIBHM – Université Libre de Bruxelles, ULB, Campus Erasme CP602, 808
route de Lennik, 1070 Brussels, Belgium
2WELBIO, 808 route de Lennik, 1070 Brussels, Belgium
Full list of author information is available at the end of the article
© 2015 Fimereli et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.however, remain conflicting. Di Lonardo et al. [3]
detected HPV DNA in nearly 30% of ductal breast
carcinomas when using polymerase chain reaction
(PCR). A number of studies from various research
groups followed. Viruses that have been mainly de-
tected and linked to breast cancer include HPV
types 16 and 18, EBV and human herpesvirus type 5
(CMV) [4-9]. In contrast, studies were published
that failed to detect viral sequences in breast cancer
[10,11]. Apart from the above viruses, the mouse
mammary tumor virus (MMTV) has also been in
the center of attention, due to its link with mam-
mary cancer in mice, with a recent study detecting
MMTV sequences in the milk of women who had
undergone breast biopsies [12]. The review of Salmons
et al. [13] points out, as mentioned above for the other vi-
ruses, the controversy in the results between studies for
the presence or not of MMTV in breast cancer and the
fact that viral sequences are difficult to detect in tumors.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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situ hybridization (ISH). These technologies require
prior assumptions about which viruses might be associ-
ated with breast cancer. In contrast, next generation
sequencing (NGS) technologies make it feasible to
directly detect viral sequences without any a priori
assumption regarding the virus involved. A small
number of studies have exploited transcriptome NGS
in order to detect viral sequences in cutaneous squa-
mous cell carcinoma, non-Hodgkin’s Diffuse Large
B-Cell Lymphoma and other cancer types [14,15].
Recently, two studies have scanned transcriptome se-
quences from The Cancer Genome Atlas (TCGA),
which contains several thousands of human samples
from 20 cancer types, for transcribed viral sequences
[16,17]. No viral sequence could be detected in the
pool of TCGA breast cancers examined in the two
studies, 750 and 810, respectively.
There are currently a number of computational algo-
rithms available for detecting pathogen sequences using
NGS data for example PathSeq [18] or VirusSeq [19].
The majority of them involve an initial step of subtrac-
tion of human sequences and the subsequent alignment
of the remaining non-human sequences to a database of
pathogen sequences (which can include viral, bacterial
or fungal sequences). The differences between these
tools are based mainly on the aligners used at each step
of the procedure, which can produce varying results.
The aim of this study was to investigate the presence
of viral transcripts in a cohort of breast cancer samples
encompassing the known main molecular subtypes (lu-
minal A and B, triple negative and HER2 positive). In
order to accomplish our goal, we performed RNA se-
quencing and implemented five different but comple-
mentary in silico methods covering a range of available
bioinformatics techniques. In addition, we matched NGS
results against PCR and immunohistochemistry (IHC).Methods
Samples selection
A total of 58 breast cancer (BC) patients for whom
fresh-frozen tumor and normal, adjacent material as well
as formalin-fixed, paraffin embedded (FFPE) tumor ma-
terial was available at Bordet Tumor Bank (Jules Bordet
Institute, Brussels, Belgium) were selected for this pro-
ject. Patients were recruited between 2007 and 2011 and
associated clinico-pathological data are available for all.
The use of the data is consistent with the informed
consent signed by the patients or has been granted eth-
ical approval by the local Ethics Committee and is in ac-
cordance with the applicable laws and regulations of
Belgium. The study was approved by the ethics commit-
tee of Institut Jules Bordet (study number: CE1967).Samples histopathology
On the basis of their immunohistochemistry (IHC) profile,
patients were classified in one of the four main IHC BC
subtypes: triple negative (TN: estrogen receptor (ER), pro-
gesterone receptor (PgR), and human epidermal growth
factor receptor 2 (HER2) negative), HER2 positive (any ER
and PgR, HER2 positive), luminal A (ER positive, HER2
negative, histological grade 1) and luminal B (ER positive,
HER2 negative, histological grade 3).
RNA extraction
RNA from fresh-frozen material was extracted using
TRIzol® (Life Technologies, Carlsbad, California) following
the manufacturer’s instructions. RNA concentration was
defined using the NanoDrop 1000 (Thermo Scientific,
Waltham, Massachusetts), and RNA integrity (RIN: RNA
Integrity Number) was assessed using an Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, California).
All the samples yielded enough material for downstream
analyses and had a RIN equal or superior to 6.5.
DNA extraction
DNA from both tumor and normal fresh-frozen material
was extracted using DNeasy Blood and Tissue kit® (Qiagen,
Venlo, Netherlands) following the manufacturer’s instruc-
tions. DNA concentration was measured using the Nano-
Drop 1000 instrument (Thermo Scientific). All the samples
yielded enough material for downstream analyses.
RNA sequencing
Transcriptome sequencing was performed at DNAVision
(Gosselie, Belgium). Transcriptome libraries were con-
structed using the Illumina® TruSeq™ RNA Sample Prep-
aration Kit for paired end reads sequencing on the
HiSeq 2000 (Illumina, San Diego, California) following
the manufacturer’s instructions.
Briefly, starting from 1 μg of total RNA, the poly-A
containing mRNA molecules was purified using poly-T
oligo-attached magnetic beads. Following purification,
the mRNA was fragmented into small pieces using diva-
lent cations at elevated temperature. The cleaved RNA
fragments were copied into first strand cDNA using
reverse transcriptase and random primers. This was
followed by second strand cDNA synthesis using DNA
Polymerase I and RNase H and purification using the
AMPure XP beads (Agencourt BioSciences Corpor-
ation, Beverly, Massachusetts). The cDNA fragments
went through an end repair process, the addition of a
single ‘A’ base and ligation of the adapters. The prod-
ucts were purified using the AMPure XP beads and
enriched with PCR (15 cycles) to create the final cDNA
library followed by purification using the AMPure XP
beads. Libraries’ quality control and quantification
were performed using the Agilent Bioanalyser 2100
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Clusters were generated in a cBot Cluster Generation
System using the Paired-End Cluster Generation Kit
v2-HS and sequenced on the Illumina HiSeq 2000 plat-
form (Illumina) with a 2x50 base-pairs (BP) paired-end
mode.
Exome sequencing
Exome sequencing was performed at GATC (Konstanz,
Germany). Genomic libraries from the tumor and
matched normal samples were generated using the Illu-
mina Paired End DNA sample preparation kit (Illumina)
following the manufacturer’s instructions. Enrichment
was performed using the Agilent SureSelect Human All
Exon V3 kit (Agilent) following the manufacturer’s
instructions.
Briefly, 2–3 μg of total genomic DNA was randomly
fragmented to between 150 and 600 bp by focused
acoustic shearing (Covaris Inc, Wouburn, Massachusetts).
A cleanup was performed using AMPure beads (Agen-
court BioSciences Corporation) following the manufac-
turer’s protocol and the material quality was assessed
using the Agilent Bioanalyser 2100 (Agilent).
The size-fractionated DNA was end repaired using T4
DNA polymerase, Klenow polymerase and T4 poly-
nucleotide kinase and purified using AMPure beads. The
resulting blunt ended fragments were A-tailed using a
3′-5′ exonuclease-deficient Klenow fragment, purified
using AMPure beads and ligated to Illumina paired-end
adaptor oligonucleotides in a ‘TA’ ligation at 20°C for
15 minutes. The product was purified using AMPure
`beads. After estimation of the concentration, the adaptor-
ligated library was amplified and then purified using
AMPure beads. Quality and quantity were assessed using
a 2100 Bioanalyzer (Agilent).
The enriched regions were captured, purified, PCR
amplified and purified using AMPure beads. After quan-
tification and quality control of the captured library,
samples were pooled (four samples/lane) for loading on
an Illumina HiSeq 2000. Samples were sequenced in
paired-end mode, with a read length of 2x100 bases.
Transcriptome and exome read mapping
RNA-seq reads were mapped with the Burrows-Wheeler
Aligner [20] (BWA v0.5.9) simultaneously on the human
reference genome (hg19) and a library of splice junc-
tions. Reads were mapped with command ‘bwa aln –n 6’
to report up to 6 matches per reads with multiple
matches so that read pairing could be performed with a
custom perl script considering the true distance between
mates after removal of intronic regions between them.
Further, we removed all non-unique and discordant read
pairs. The splice junctions library was constructed by
concatenating respectively the last and first 50 nucleotidesfor each pair of consecutive exons. We used gene annota-
tions from Refseq, UCSC, Ensembl and Gencode, down-
loaded from the UCSC Table Browse [21]. Exome-seq
reads were also mapped to the hg19 reference genome
using BWA, with default options. For both transcriptome
and exome alignments, we further removed duplicates
with Picard’s MarkDuplicates utility (http://broadinstitute.
github.io/picard) (v1.59) and performed local realignment
using the GATK’s IndelRealigner program [22] (v1.4-15).
Computational detection of viral sequences using RNA-Seq
In pipeline 1, all reads not mapped to the human gen-
ome or human splice junctions were aligned to the
RefSeq database of viral genomes (n = 4537), with BWA
(v0.6.1) with default parameters. All reads that aligned to
a viral genome were considered as potential viral reads
and were further aligned using blastn [23] (v2.2.28) (with
default parameters) against the NCBI nucleotide (nt)
database. Reads with the best blast hit (lowest e-value
and highest alignment score) matching the BWA virus
hit were considered of true viral origin.
In pipeline 2, unmapped reads were aligned to the
RefSeq viral database with the use of blastn instead of
BWA (blastn was run with default values and e-value of
e-05). All reads that aligned to a viral genome were con-
sidered as potential viral reads and were further aligned
to the nt database as in the previous pipeline.
In pipeline 3, we performed a de novo assembly on the
unmapped reads using Trinity [24] (trinityrnaseq-r2013-
02-25) with default values and kept all contiguous seg-
ments (contigs) with length > 100 bp. These contigs were
then aligned using blastn (megablast with default values
and an e-value of e-05) against the RefSeq viral database.
Contigs with a viral hit were further aligned against the
nt database and analyzed as in the two previous steps.
In pipeline 4 we used TriageTools [25] (v0.2.0), a tool
that efficiently screens input reads for similarity to a spe-
cific target sequence. TriageTools was utilized with de-
fault parameters, the raw reads as input and as target
the RefSeq sequences of HPV types 16 and 18 and HHV
types 4 and 5. At a later stage we added to the pool of
viruses, HHV 6B, Merkel cell polyomavirus and high-
risk HPV viruses (as explained in the Results section).
After obtaining the hit reads from TriageTools (reads
that match the target sequence), we aligned them to the
corresponding viral genome (target sequence) with
BWA. All reads aligned to the viral genome where fur-
ther aligned against the nt database with blastn and ana-
lyzed as in the previous steps.
In the pipeline 5, VirusSeq [19], a published bioinfor-
matics pipeline for the detection of viruses was used.
VirusSeq accepts the raw reads as input. Although it
uses an empirical cut-off of 1000 reads for virus detec-
tion, the user can manually examine the number of
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base and identify the viral reads of his/her interest (even
with a number of reads below this cutoff ).
Computational detection of viral sequences using Exome-Seq
We applied pipelines 1–4 to those samples where true
viral sequences were detected in the RNA-seq reads. All
pipelines (with the exception of pipeline 1) were adjusted
to better fit the larger read size of the exome sequences.
In the second pipeline we used megablast instead of
blastn. In the third pipeline we performed a de novo as-
sembly with Trinity on the unmapped reads as previ-
ously described, however we increased the length of the
contigs to >200 bp. In the fourth pipeline we increased
the hits parameter to 72 instead of the default 36.
Positive control sequences
As it is essential to test the efficiency of the different
pipelines, we decided to use a control dataset of RNA
sequences as a positive control. We obtained the hepato-
cellular carcinoma RNA-Seq test set accompanying the
VirusSeq algorithm. In the VirusSeq publication the
same set was used for testing purposes and hepatitis B
virus transcripts and viral integration loci were detected.
The different pipelines were tested with this test set in
order to identify the most abundant virus present.
EBV IHC
For each sample, a representative FFPE block containing
invasive adenocarcinoma was selected and a 4 μm-thick
slice was cut.
EBV IHC was performed as follows: briefly, sections
were de-paraffinized and processed using the Ventana
detection system with the iViewTM DAB detection kit
(Ventana, Tucson, Arizona). Antigen retrieval was per-
formed with EDTA (Tris/borate/EDTA; pH 8.4). The
slides were then incubated in a prediluted solution of
Monoclonal Mouse Anti-EBV, LMP Clone CS.1-4 (DAKO,
code IS753) at room temperature for 32 minutes. After
staining, slides were processed in accordance with routine
protocols.
DNA extraction
DNA from FFPE material was extracted using QIAamp
DNA FFPE Tissue kit® (Qiagen,) following the manufac-
turer’s instructions. DNA concentration was measured
using the NanoDrop 1000 instrument (Thermo Scien-
tific). All samples yielded enough material for down-
stream analyses.
HPV PCR
PCR was performed using the Cobas® 4800 HPV Ampli-
fication/Detection kit (Roche, Basel, Switzerland) on the
COBAS Z4800 instrument. This test is a qualitativein vitro test for the detection of HPV in the clinical set-
ting. The test utilizes amplification of target DNA by
PCR and nucleic acid hybridization for the detection of
14 high-risk (HR) HPV types in a single analysis. The
test specifically identifies (types) HPV 16 and HPV 18
while concurrently detecting the rest of the high-risk
types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) at
clinically relevant infection levels. ß-globin was used as
an internal control.
Results
Five virus detection pipelines successfully recovered
hepatitis B virus (HBV) transcripts in a hepatocellular
carcinoma
The four in-house and one published virus detection
pipelines we implemented are depicted in Figure 1. Pipe-
lines 1–3 and 5 first select reads that cannot be mapped
to the human genome and attempt to map them on the
RefSeq viral genome database and Gib-V database, re-
spectively. In pipelines 1–3, reads with a viral hit are
then screened against a comprehensive general-purpose
sequence database (NCBI’s Non Redundant, NR) in
order to further rule out their human origin. Reads with
better BLAST hits to human than viral sequences are
discarded. Pipelines 1–3 use the same initial alignment
step and the same final filtering step (see Methods).
However, they rely on different strategies for the viral se-
quences alignment. Pipeline 1 uses BWA, a standard
short read aligner in NGS studies; pipeline 2 uses
BLAST, a decade-old, proven aligner; pipeline 3 attempts
to circumvent the limits of short reads by inserting a de
novo assembly step before the viral screening. Pipeline 5
(VirusSeq) is conceptually similar to pipeline 1, but was
set up by an independent team who took different tech-
nical routes at all steps of the implementation.
Pipelines 1–3 and 5 are unbiased with respect to
which virus may be associated with breast, and poten-
tially other, cancers. This valuable property comes at the
cost of aligning the transcriptomes onto the human gen-
ome—an error-prone computational task. By contrast,
pipeline 4 implements a targeted search limited to 4 vi-
ruses putatively associated with breast cancer, but it
eliminates the initial human genome-mapping step. In-
stead, the transcriptome reads mapping to target viral
genomes are selected directly with TriageTools, an in
silico equivalent of the in vitro hybridization-based se-
quence capture.
As a positive control, we ran the five pipelines on a
published RNA-Seq test set of hepatocellular carcinomas
provided by the VirusSeq tool. All of the pipelines cor-
rectly detected HBV as the most abundant virus, repre-
senting 0.1‰ of all reads (~50,000 reads) with pipelines
1–2, 4 and 5. Pipeline 3 assembled two HBV contigs of
3129 bp and 170 bp.
Figure 1 Computational pipelines for the detection of non-human sequences. Five different pipelines were used in this study. In pipelines
1, 2 and 3 raw reads were first aligned to the human genome and the unmapped reads were then used for alignment to the viral database with
BWA, for alignment to the viral database with BLAST, and for de novo assembly and alignment to the viral database, respectively. In pipelines 4 and 5,
raw reads were given as input to TriageTools and VirusSeq, respectively.
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cancer transcriptomes
Illumina HiSeq2000 transcriptome sequencing was per-
formed on 58 breast cancers, producing a median of
64,792,160 2x50 bp reads per samples. The five pipelines
described above were applied; the obtained results are
provided in Table 1.
In the first step of pipelines 1–3, the raw reads were
mapped to the human genome with a median of
1,029,23 unmapped reads remaining for further viralsequences scanning. The most abundant non-human se-
quences detected by pipelines 1–3 were from Enterobac-
teria phage phiX174. This phage is used as a control
during sequencing and should be viewed as a positive
control, not a biologically relevant finding. A small num-
ber of reads were detected by pipelines 1, 2 and 5 that
were mapped to human viruses by their full length and
were considered as of true viral origin: 1) Two reads
mapped to EBV in one sample; 2) three reads mapped to
the Merkel cell polyomavirus in one sample; 3) a total of
















Test Set NA 424484976 46821 50681 2 45071 43466 HBV
HER2-
13
46 64893130 0 0 0 0 0 negative negative
HER2-
14




45 61599108 0 0 0 0 0 negative negative
HER2-
16
58 61491812 0 0 0 0 0 negative negative
HER2-
18
38 67873006 0 0 0 0 0 negative negative
HER2-
19
60 67894004 22 (27) 25 (27) 0 (0) 17 (27) 26 HHV6 negative negative
HER2-2 83 59452650 0 0 0 0 0 negative negative
HER2-
20
66 85761124 0 0 0 0 0 negative negative
HER2-
21
46 93380848 0 0 0 0 0 negative negative
HER2-
22
39 50262908 0 0 0 0 0 negative negative
HER2-
23
55 68452272 0 0 0 0 0 failure negative
HER2-
24
49 45799400 0 0 0 0 0 negative negative
HER2-3 35 59739682 0 0 0 0 0 negative negative
LA-18 63 50984238 0 0 0 0 0 negative negative
LA-19 37 83958354 0 0 0 0 0 negative positive
hpv16
LA-20 50 32869722 0 0 0 0 0 negative negative
LA-21 51 76552678 0 0 0 0 0 negative negative
LA-22 62 60308476 0 0 0 0 0 negative negative
LA-23 73 42225858 0 0 0 0 0 negative negative
LA-24 63 39585066 0 0 0 0 0 negative NA
LA-25 58 49913768 0 0 0 0 0 negative NA
LA-26 66 72421722 0 0 0 0 0 negative negative
LA-27 62 66523668 0 0 0 0 0 negative negative
LA-28 64 64969514 0 0 0 0 0 negative NA
LA-29 51 23434748 0 0 0 0 0 negative negative
LA-31 85 79158278 0 0 0 0 0 negative NA
LA-32 58 68369496 0 0 0 0 0 negative NA
LA-33 68 75436316 0 0 0 0 0 NA negative
LA-4 61 64916390 0 0 0 0 0 negative negative
LB-1 42 70818118 0 0 0 0 0 negative negative
LB-3 53 44475406 0 0 0 0 0 negative negative
LB-5 42 58896182 0 0 0 0 0 NA NA
LB-15 79 37855250 0 0 0 0 0 negative negative
LB-17 57 71008672 0 0 0 0 0 negative negative
LB-18 61 56839562 0 0 0 0 0 negative NA
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Table 1 Viral sequences detected in the samples with the use of several computational methods (Continued)
LB-19 34 66451162 2 (4) 2 (4) 0 (0) 2 (4) 2 EBV negative negative
LB-20 45 114639766 0 0 0 0 0 negative negative
LB-21 51 64647066 0 0 0 0 0 negative negative
LB-22 53 79028228 0 0 0 0 0 negative negative
LB-23 55 116825666 0 0 0 0 0 negative negative
TN-1 41 75308960 3 (0) 3 (0) 0 (0) 2(0) 3 Merkel cell
polyomavirus
negative negative
TN-2 47 107171302 0 0 0 0 0 NA NA
TN-3 59 34339412 0 0 0 0 0 negative negative
TN-5 39 44460594 0 0 0 0 0 negative negative
TN-15 35 56793532 0 0 0 0 0 NA NA
TN-16 52 71331804 0 0 0 0 0 failure negative
TN-17 34 81351348 0 0 0 0 0 negative negative
TN-18 62 84104974 0 0 0 0 0 negative negative
TN-19 50 19621240 0 0 0 0 0 negative negative
TN-20 51 80751454 0 0 0 0 0 negative negative
TN-21 56 65225662 0 0 0 0 0 negative negative
TN-22 39 63983318 0 0 0 0 0 negative negative
TN-23 65 50443546 0 0 0 0 0 negative negative
TN-24 63 70061346 0 0 0 0 0 negative negative
TN-25 79 43789446 0 0 0 0 0 negative negative
TN-26 81 56344394 0 0 0 0 0 negative negative
TN-27 57 64691190 0 0 0 0 0 negative negative
TN-28 54 46437934 0 0 0 0 0 negative negative
The numbers in the parenthesis indicate the number of sequences detected in exome-seq analysis. Viral hits are highlighted in bold.
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6B) in one sample. The de novo approach (pipeline 3)
could not assemble viral sequences because of their
small number.
In addition to the above findings, VirusSeq (pipeline 5)
reported glyptapanteles flavicoxis bracovirus as the most
abundant virus in all samples. This non-human false
positive hit comes from the alignment of sequences with
long stretches of “TG”.
The targeted approach (pipeline 4) was run initially
with HPV 16 and 18 and EBV and CMV as targets. At a
later stage we added to the list of viruses HHV 6B and
Merkel cell polyomavirus as these two viruses were de-
tected by the unbiased methods. High-risk human papil-
lomaviruses were also added since DNA sequence was
detected in one sample by PCR (see below). All hits
from unbiased approaches, but not the PCR hits (see
below), were recovered.
Viral expression confirmed by exome sequencing but not
confirmed by PCR or IHC
To validate these results, we ran the approaches 1–4
using exome sequences on the three samples where viralsequences were detected in the transcriptome sequen-
cing data/reads. Pipelines 1, 2 and 4 successfully de-
tected four reads of EBV and 27 reads of HHV 6B.
Merkel cell polyomavirus was not recovered in the ex-
ome data by any of our approaches. As previously, the
pipeline 3 could not assemble any viral sequences.
We next sought for the presence of EBV using IHC in
54 of the samples, and for the presence of HPV se-
quences using PCR in 49 samples. No EBV viral DNA
was detected in any of the samples, including those posi-
tive with the transcriptome sequencing assay. On the
contrary, we identified one positive sample for HPV 16,
and one with high risk HPV strain, although no HPV se-
quence could be identified by both transcriptome and
exome sequencing in these samples.Discussion
In order to explore the potential role of viral infection in
breast cancers, we investigated their transcriptome se-
quences with five different in silico detection methods
while in parallel we performed exome sequencing, IHC
and PCR to detect viral infection at the DNA level.
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been so far exploited for the detection of viral sequences
in human samples both alone or in combination. We
also used a tool specifically designed for virus detection
(VirusSeq, pipeline 5) and a bioinformatics tool designed
for a more general purpose that could be applied in this
study (TriageTools, pipeline 4). TriageTools differs from
all the other methods since it searches for viral se-
quences in the raw sequenced reads without the need of
first aligning them to the human reference genome, a
step that it is known to be time-consuming. Using four
of our alignment techniques, we detected viral sequences
from EBV (2 reads), HHV6 (17–25 reads) and Merkel
cell polyomavirus (2–3 reads). However, the number of
detected viral sequences was orders of magnitude lower
than in our positive control, an HBV-associated hepato-
cellular carcinoma transcriptome containing ~50,000
HBV reads. After normalizing by the sequencing cover-
age, viral reads represented at most 0.0004‰ of all the
reads in our samples, compared to 0.1‰ in the positive
control. Given the high prevalence of HHV 4 and 6,
contamination, rather than a productive viral infection,
is a possibility.
In parallel, we performed IHC on slides obtained from
FFPE blocks from the same patients to detect the pres-
ence of EBV. In addition, the presence of HPV was in-
vestigated with a PCR assay routinely used in the clinic.
No sample tested positive for EBV. Two samples were
tested positive for HPV, although no HPV sequences
were found in the transcriptomes and exomes of these
samples. These discrepancies could result from a higher
sensitivity of the PCR-based assay. It is also possible that
the viruses identified with PCR are integrated in the
DNA of these two patients, but not expressed, or it can
be the result of the already reported heterogeneity of
viral integration in human exome [26]. Heterogeneity in
the distribution of the HHV 4 genome between regions
of the same tumor as well as among different tumors
was observed by Arbach et al. [27]. Additionally, they
have found differences in the viral load, when they fo-
cused within one region or in the whole tumor. Al-
though, a very low viral load is possibly not being
detected by PCR, the advantages of next generation se-
quences would allow the detection of viral sequences
even in small numbers thus making our techniques suit-
able for detecting small viral loads.
All our methods were successful at detecting viral se-
quences in the test set, but only a small number of viral
sequences were detected in our breast cancer samples. A
possible explanation could be a hit-and-run mechanism,
where a virus infects the target tissue, performs a muta-
genic action that makes the cell malignant and is then
lost and therefore not detectable [28]. However, cases of
hit-and-run mechanism are very difficult to detect.Another explanation is the fact that some viruses can
contribute to carcinogenesis without being expressed, as
is the case of the MMTV. In cases such as the two
above, the RNA-seq technology is limited by the fact
that it can only detect expressed viral sequences.
Although very few viral sequences of those known vi-
ruses were detected in our samples, further studies of
other viruses could be of great interest. As mentioned in
the recent review of Salmons et al. [29], there is accumu-
lating evidence that retroviruses like MMTV are associ-
ated with breast cancer. However, retroviruses that are
already integrated in the human genome (human en-
dogenous retroviruses) could be of potential interest as
well. Evidence of polymorphism in the integration of
such endogenous viruses, as shown by Marchi et al. [30]
and studies showing the detection of those sequences in
breast cancer, could lead to a new viral agent linked to
breast cancer.
Conclusions
Our study demonstrates the ability to detect expressed
viral sequences in breast cancer samples. The small
number of those sequences indicates that there is no
high enough expression to be able to conclude for a viral
cause for breast carcinogenesis in our samples. However,
it does not exclude the presence of integrated but silent
viral sequences in the breast tumor genome or a possible
hit-and-run mechanism. Further similar studies using
whole genome sequencing are warranted on this subject.
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